Abbot Laboratories
The patent covers the evaluation of patients suitable for therapy by Bcl-2 inhibitors (ABT-263, ABT-737). The patient is profiled for deletions in the region of microRNAs miR-15a, miR-16-1, and miR-34c. Flourescence in-situ hybridization (FISH) is used for analysis.
[patent:WO/2008/082643]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment